arrow_back Trending Legislation
Share share

Support for Serious Infection Drugs: New Rules for Biological Products

This act aims to accelerate access to new drugs and biological products that combat serious and life-threatening infections, including antibiotic-resistant ones. This means citizens can receive innovative therapies faster, increasing the chances of effective treatment for difficult diseases.
Key points
Expands the definition of "qualified infectious disease products" to include biological products, meaning more support for their development.
Allows for faster review and approval by regulatory bodies of drugs and biological products intended to combat serious infections.
Focuses on drugs that fight bacteria and fungi, including those resistant to existing therapies, which is crucial for public health.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
GAIN TOOLS Act of 2022
Print number: S 3478
Sponsor: Sen. Casey, Robert P., Jr. [D-PA]
Process start date: 2022-01-11
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Support for Serious Infection Drugs: New Rules for Biological Products

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 3478.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-01-11.

What are the main provisions?

Key points include:

  • Expands the definition of "qualified infectious disease products" to include biological products, meaning more support for their development.
  • Allows for faster review and approval by regulatory bodies of drugs and biological products intended to combat serious infections.
  • Focuses on drugs that fight bacteria and fungi, including those resistant to existing therapies, which is crucial for public health.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Casey, Robert P., Jr. [D-PA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Analysis and Potential Impact of S 3478

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health